Understand the source comparison
AOD-9604's Mechanism vs Growth Hormone Secretagogues
Growth hormone secretagogues. Ipamorelin, GHRP-2, GHRP-6, CJC-1295. Bind to ghrelin receptors (GHS-R1a) in the pituitary gland, triggering pulsatile release of endogenous growth hormone. That release elevates plasma IGF-1 (insulin-like growth factor 1), which
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth hormone secretagogues. Ipamorelin, GHRP-2, GHRP-6, CJC-1295. Bind to ghrelin receptors (GHS-R1a) in the pituitary gland, triggering pulsatile release of endogenous growth hormone. That release elevates plasma IGF-1 (insulin-like growth factor 1), which drives anabolic processes including muscle protein synthesis, bone density increases, and enhanced lipolysis. The lipolytic effect is downstream and indirect: growth hormone activates hormone-sensitive lipase (HSL) in adipocytes, but it also upregulates glucose production, increases insulin resistance temporarily during acute spikes, and stimulates tissue growth across multiple organ systems.
- AOD-9604 bypasses that entire cascade. It's a modified fragment of hGH's C-terminus that retains the peptide's beta-3 adrenergic receptor binding capacity without activating growth hormone receptors. The practical difference: AOD-9604 stimulates lipolysis directly at the adipocyte without requiring pituitary signalling, without elevating systemic IGF-1, and without affecting glucose metabolism. Published preclinical data in obese Zucker rats demonstrated that AOD-9604 reduced body weight gain by 50% over 14 days compared to controls. With no detectable increase in serum IGF-1 or insulin levels. Growth hormone secretagogues would have elevated both.
- Our team has found that researchers working with metabolic models often prefer AOD-9604 over secretagogues specifically because it isolates the lipolytic variable. If your protocol requires measuring fat oxidation without confounding IGF-1-driven anabolic effects, AOD-9604 delivers that isolation. Real Peptides synthesises AOD-9604 through small-batch sequencing with third-party purity verification, ensuring each vial contains the exact 176-191 amino acid sequence. No truncated fragments, no impurities that could trigger unintended receptor cross-reactivity.